Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 14, 2023
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 12, 2023
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research April 20, 2023
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330 February 27, 2023
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 15, 2022
